枸地氯雷他定联合布地奈德治疗鼻窦炎患者的效果

Effectiveness of Loratadine Citrate in Combination with Budesonide in the Treatment of Patients with Sinusitis

目的 探讨对鼻窦炎患者予以枸地氯雷他定联合布地奈德治疗的临床疗效。方法 便利选择2018年6月—2021年6月中国药科大学第一附属医院收治的180例鼻窦炎患者,随机分为术后使用布地奈德喷鼻的对照组(n=90)与联合枸地氯雷他定治疗的观察组(n=90),比较两组临床疗效,检测治疗前后总免疫球蛋白E(TIgE)、嗜酸性粒细胞(EOS)、EOS阳离子蛋白(ECP),另检测血清高敏C反应蛋白(hs-CRP)、白介素(IL)-6、IL-8水平,并统计不良反应发生率。结果 观察组总有效率较对照组高(95.00%vs 77.50%),差异有统计学意义(χ^(2)=5.165,P<0.05)。观察组治疗后TIgE(57.24±5.18)kU/L、EOS(3.05±0.65)%、ECP(4.27±0.75)ng/L,均小于对照组,差异有统计学意义(t=5.121、4.499、5.484,P<0.05)。观察组治疗后hs-CRP(2.91±0.35)ng/L、IL-6(7.14±2.01)pg/mL、IL-8(285.50±34.15)ng/mL,均小于对照组,差异有统计学意义(t=18.525、7.127、5.041,P<0.05)。两组不良反应发生率(12.50%vs 7.50%)对比,差异无统计学意义(χ^(2)=0.139,P>0.05)。结论 对鼻窦炎患者在布地奈德治疗基础上联合枸地氯雷他定治疗能提高疗效,可改善机体变态反应及炎症反应,用药安全可靠。

Objective To investigate the clinical efficacy of giving loratadine citrate combined with budesonide to pa⁃tients with sinusitis.Methods One hundred and eighty patients with sinusitis admitted to the First Affiliated Hospital of China Pharmaceutical University from June 2018 to June 2021 were conveniently selected and randomly divided into a control group(n=90)treated with budesonide nasal spray after surgery and an observation group(n=90)treated with combined loratadine citrate.The clinical efficacy,total immunoglobulin E(TIgE),eosinophil(EOS),and EOS cat⁃ionic protein(ECP)were tested before and after treatment of the two groups was compared.Serum high-sensitivity C-reactive protein(hs-CRP),interleukin(IL)-6 and IL-8 levels were also measured.And the adverse reaction rate was counted.Results The total effective rate of the observation group was higher than that of the control group(95.00%vs 77.50%),the difference was statistically significant(χ^(2)=5.165,P<0.05).TIgE(57.24±5.18)kU/L,EOS(3.05±0.65)%and ECP(4.27±0.75)ng/L after treatment in the observation group were smaller than those in the control group,the difference was statistically significant(t=5.121,4.499,5.484,P<0.05).The hs-CRP(2.91±0.35)ng/L,IL-6(7.14±2.01)pg/mL,IL-8(285.50±34.15)ng/mL after treatment in the observation group were smaller than those in the con⁃trol group,the difference was statistically significant(t=18.525,7.127,5.041,P<0.05).There was no statistically sig⁃nificant difference in the rate of adverse reactions between the two groups(12.50%vs 7.50%)(χ^(2)=0.139,P>0.05).Conclusion Combining loratadine citrate with budesonide treatment in patients with rhinosinusitis can improve the ef⁃ficacy,improve the body's metabolic and inflammatory response,and the medication is safe and reliable.